TravisJasonHollmannMD

Dermatopathology, Anatomic Pathology, Clinical Pathology

Assistant Professor

Dr. Hollmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1275 York Avenue
Memorial Hospital/ Dept. Of Pathology
New York, NY 10065
Phone+1 212-639-8134

Beth Israel Deaconess Medical Center/Harvard Medical SchoolFellowship, Dermatopathology, 2008 - 2009
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 2005 - 2008
McGovern Medical School at UTHealthClass of 2005

PubMed

Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.
Janis M Taube, Joel C Sunshine, Michael Angelo, Guray Akturk, Margaret Eminizer
Journal for Immunotherapy of Cancer. 2025-01-08
2 citations
Progressive plasticity during colorectal cancer metastasis.
Andrew Moorman, Elizabeth K Benitez, Francesco Cambulli, Qingwen Jiang, Ahmed Mahmoud
Nature. 2025-01-01
Author Correction: Progressive plasticity during colorectal cancer metastasis.
Andrew Moorman, Elizabeth K Benitez, Francesco Cambuli, Qingwen Jiang, Ahmed Mahmoud
Nature. 2025-01-01

Journal Articles

Massively Parallel Sequencing Analysis of Benign Melanocytic Nevi
Allan C Halpern, Travis J Hollmann, Klaus J Busam, Histopathology
Microenvironment-Derived Factors Driving Metastatic Plasticity in Melanoma
Liang Lu, Travis Hollmann, Nature

Abstracts/Posters

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
Travis Hollmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportMarch 12th, 2021
For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor SizeMarch 26th, 2019